Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison

It is suggested that zanubrutinib offers improved PFS over FCR in fit, treatment-naive patients with CLL, further supporting zanubrutinib as a first-line CLL treatment for multiple patient profiles.

T. Munir, L. Barnieh, L. Mohseninejad et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.